Congress blocks Medicare cost-control rule; healthcare stocks rally
S.J.Res. 198 — A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model". · Filed by Ron Wyden (D-OR) · 21 cosponsors · Introduced Jun 24, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This is a Congressional Review Act resolution that would block the Centers for Medicare & Medicaid Services from implementing a new rule requiring prior authorization (advance approval) for certain Medicare services deemed wasteful or inappropriate under the WISeR Model. If passed, the rule would be nullified and CMS could not reissue it without new congressional authorization.
Why we flagged it
This is a procedural CRA resolution under 5 U.S.C. § 802 that seeks to nullify an executive agency rule. It does exactly one thing: disapprove the WISeR prior authorization rule and prevent its enforcement.
What the text implies
- Blocking prior authorization may preserve higher Medicare spending on services CMS deemed wasteful, increasing program costs and taxpayer burden.
- The resolution protects pharmaceutical, medical device, and healthcare service providers from utilization controls that would reduce their service volume and revenue.
- If passed, CMS would need explicit congressional approval to reissue any similar prior authorization rule, raising the bar for future cost-containment measures.
- The bipartisan sponsorship (led by Wyden, a Democrat, with 21 cosponsors including Republicans) suggests healthcare industry alignment across party lines against the rule.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The resolution blocks a cost-control measure that could reduce unnecessary medical procedures and lower Medicare spending, which benefits taxpayers and the program's solvency. However, it also prevents a tool that could reduce patient access to services by requiring advance approval, which may harm beneficiaries who face delays or denials. The balance depends on whether WISeR's prior authorization requirements would have been appropriately targeted or overly restrictive.
Who stands to gain
- pharmaceutical manufacturers
- medical device companies
- healthcare service providers
- dialysis centers
- specialty pharmacies
Named in the bill
Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), WISeR Model (Wasteful and Inappropriate Services Reduction), Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), Congressional Review Act, Government Accountability Office (GAO)
Where it stands
21 cosponsors: 20 Democrats, 1 Independents.
- Jun 24, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jun 24, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”
- Jun 24, 2026 — Reported out of committee · Congress.gov: “Senate Committee on Finance discharged, by petition, pursuant to 5 U.S.C. 802(c)”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $410,000 in lobbying spend. A filing names 166 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Ron Wyden, the sponsor, reported $375,070 in PAC receipts in the 2026 cycle.
- American Federation of Teachers — $410,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,201 characters) on Jul 2, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress blocks Medicare cost-control rule; healthcare stocks rally” QuorumCivic. https://share.quorumcivic.app/bill/119/sjres198 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.